777 related articles for article (PubMed ID: 34756770)
1. Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia.
Gordon SF; Clothier HJ; Morgan H; Buttery JP; Phuong LK; Monagle P; Chunilal S; Wood EM; Tran H; Szer J; Crawford NW;
Vaccine; 2021 Nov; 39(48):7052-7057. PubMed ID: 34756770
[TBL] [Abstract][Full Text] [Related]
2. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
Osowicki J; Morgan HJ; Harris A; Clothier HJ; Buttery JP; Kiers L; Crawford NW;
Vaccine; 2022 Dec; 40(52):7579-7585. PubMed ID: 36357291
[TBL] [Abstract][Full Text] [Related]
3. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
Welsh KJ; Baumblatt J; Chege W; Goud R; Nair N
Vaccine; 2021 Jun; 39(25):3329-3332. PubMed ID: 34006408
[TBL] [Abstract][Full Text] [Related]
4. A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
Kim G; Choi EJ; Park HS; Lee JH; Lee JH; Lee KH
J Korean Med Sci; 2021 Nov; 36(43):e306. PubMed ID: 34751013
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
[TBL] [Abstract][Full Text] [Related]
6. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.
Deng L; Glover C; Dymock M; Pillsbury A; Marsh JA; Quinn HE; Leeb A; Cashman P; Snelling TL; Wood N; Macartney K
Med J Aust; 2022 Aug; 217(4):195-202. PubMed ID: 35781813
[TBL] [Abstract][Full Text] [Related]
7. Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia.
Ruzicka M; Wurm S; Lindner L; Dreyling M; von Bergwelt-Baildon M; Boeck S; Giessen-Jung C; Milani V; Stemmler JH; Subklewe M; Weigert O; Spiekermann K
Infection; 2023 Feb; 51(1):231-238. PubMed ID: 36195695
[TBL] [Abstract][Full Text] [Related]
8. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of Immune Thrombocytopenic Purpura with Intracranial Hemorrhaging and Duodenal Bleeding Following SARS-CoV-2 Vaccination.
Baba Y; Sakai H; Kabasawa N; Harada H
Intern Med; 2022 Jun; 61(12):1891-1895. PubMed ID: 35400701
[TBL] [Abstract][Full Text] [Related]
10. Exacerbation of immune thrombocytopenia following initial and booster vaccination with Pfizer-BioNTech COVID-19 vaccine.
Aharoni M; Leader A; Shochat T; Raanani P; Spectre G
Platelets; 2022 Jul; 33(5):781-786. PubMed ID: 35536172
[TBL] [Abstract][Full Text] [Related]
11. Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.
MacIntyre CR; Veness B; Berger D; Hamad N; Bari N
Vaccine; 2021 Aug; 39(34):4784-4787. PubMed ID: 34272095
[TBL] [Abstract][Full Text] [Related]
12. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
13. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US.
Li X; Burn E; Duarte-Salles T; Yin C; Reich C; Delmestri A; Verhamme K; Rijnbeek P; Suchard MA; Li K; Mosseveld M; John LH; Mayer MA; Ramirez-Anguita JM; Cohet C; Strauss V; Prieto-Alhambra D
BMJ; 2022 Oct; 379():e071594. PubMed ID: 36288813
[TBL] [Abstract][Full Text] [Related]
14. Uncommon thrombotic complications after SARS-CoV-2 vaccination.
Musil D
Vnitr Lek; 2021; 67(5):297-302. PubMed ID: 35459396
[TBL] [Abstract][Full Text] [Related]
15. Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil.
Mouta Nunes de Oliveira P; Mendes-de-Almeida DP; Bertollo Gomes Porto V; Crespo Cordeiro C; Vitiello Teixeira G; Saraiva Pedro R; Roberto Gomes Takey P; Kegele Lignani L; Reis Xavier J; Cardoso Doria da Gama V; Amorim Filho L; Emoingt Furtado B; Santa Maria A; Dahrug Barros T; Neves Waite Freitas L; Dos Santos Pereira T; Lima Abreu D; Bernardes Ramos M; Gabe C; Arnold D; William Smith J; Nazy I; Lourdes de Sousa Maia M;
Vaccine; 2022 Aug; 40(33):4788-4795. PubMed ID: 35779962
[TBL] [Abstract][Full Text] [Related]
16. Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine without Thrombotic Thrombocytopenia Syndrome (TTS) in a Healthy Woman.
Alhashim A; Hadhiah K; Al Khalifah Z; Alhaddad FM; Al ARhain SA; Bin Saif FH; Abid A; Al Gamdi O; Alsulaiman F; AlQarni M
Am J Case Rep; 2022 Feb; 23():e934744. PubMed ID: 35136010
[TBL] [Abstract][Full Text] [Related]
17. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.
Simpson CR; Shi T; Vasileiou E; Katikireddi SV; Kerr S; Moore E; McCowan C; Agrawal U; Shah SA; Ritchie LD; Murray J; Pan J; Bradley DT; Stock SJ; Wood R; Chuter A; Beggs J; Stagg HR; Joy M; Tsang RSM; de Lusignan S; Hobbs R; Lyons RA; Torabi F; Bedston S; O'Leary M; Akbari A; McMenamin J; Robertson C; Sheikh A
Nat Med; 2021 Jul; 27(7):1290-1297. PubMed ID: 34108714
[TBL] [Abstract][Full Text] [Related]
18. Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to prepandemic patients.
Choi PY; Hsu D; Tran HA; Tan CW; Enjeti A; Chen VMY; Merriman E; Yong ASM; Simpson J; Gardiner E; Cherbuin N; Curnow J; Pepperell D; Bird R
Res Pract Thromb Haemost; 2023 Jan; 7(1):100009. PubMed ID: 36531670
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: A systematic review of reported cases.
Saluja P; Gautam N; Yadala S; Venkata AN
Thromb Res; 2022 Jun; 214():115-121. PubMed ID: 35533526
[TBL] [Abstract][Full Text] [Related]
20. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
Jarius S; Bieber N; Haas J; Wildemann B
J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
